Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas

P. S. Anderson, Harriet O. Smith, J. G. Jones, G. L. Goldberg, A. L. Fields, C. D. Runowicz, J. W. Pollard

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25- 50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25-50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.

Original languageEnglish (US)
Pages (from-to)202-207
Number of pages6
JournalGynecologic Oncology
Volume74
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Macrophage Colony-Stimulating Factor
Sarcoma
Macrophage Colony-Stimulating Factor Receptors
Staining and Labeling
Neoplasms
Adenocarcinoma
mannosulfan
Progesterone Receptors
Mitosis
Estrogen Receptors
Uterus
Extracellular Matrix
Virulence
Immune Sera
Intercellular Signaling Peptides and Proteins
Breast
Rabbits

Keywords

  • Colony-stimulating factor-1 (CSF-1)
  • CSF-1 receptor (c-fms)
  • Uterine sarcomas

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Anderson, P. S., Smith, H. O., Jones, J. G., Goldberg, G. L., Fields, A. L., Runowicz, C. D., & Pollard, J. W. (1999). Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas. Gynecologic Oncology, 74(2), 202-207. https://doi.org/10.1006/gyno.1999.5446

Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas. / Anderson, P. S.; Smith, Harriet O.; Jones, J. G.; Goldberg, G. L.; Fields, A. L.; Runowicz, C. D.; Pollard, J. W.

In: Gynecologic Oncology, Vol. 74, No. 2, 1999, p. 202-207.

Research output: Contribution to journalArticle

Anderson, PS, Smith, HO, Jones, JG, Goldberg, GL, Fields, AL, Runowicz, CD & Pollard, JW 1999, 'Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas', Gynecologic Oncology, vol. 74, no. 2, pp. 202-207. https://doi.org/10.1006/gyno.1999.5446
Anderson, P. S. ; Smith, Harriet O. ; Jones, J. G. ; Goldberg, G. L. ; Fields, A. L. ; Runowicz, C. D. ; Pollard, J. W. / Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas. In: Gynecologic Oncology. 1999 ; Vol. 74, No. 2. pp. 202-207.
@article{9c065d2014bb4ca09a380df6d0fe20b1,
title = "Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas",
abstract = "Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1{\%} had staining in less than 25{\%} of the tumor, 36.9{\%} had staining in 25- 50{\%} of the tumor, and only 21{\%} had staining in greater than 50{\%} of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6{\%} had negative to mild staining, and 47.4{\%} had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6{\%} of tumors had expression in less than 25{\%} of cells, 21.0{\%} had expression in 25-50{\%} of the tumor, and 26.4{\%} had staining in greater than 50{\%} of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6{\%} of the cases, moderate staining was found in 47.4{\%} of the tumors, and 21.0{\%} of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.",
keywords = "Colony-stimulating factor-1 (CSF-1), CSF-1 receptor (c-fms), Uterine sarcomas",
author = "Anderson, {P. S.} and Smith, {Harriet O.} and Jones, {J. G.} and Goldberg, {G. L.} and Fields, {A. L.} and Runowicz, {C. D.} and Pollard, {J. W.}",
year = "1999",
doi = "10.1006/gyno.1999.5446",
language = "English (US)",
volume = "74",
pages = "202--207",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Colony-stimulating factor-1 and its receptor do not have a role in the pathogenesis of uterine sarcomas

AU - Anderson, P. S.

AU - Smith, Harriet O.

AU - Jones, J. G.

AU - Goldberg, G. L.

AU - Fields, A. L.

AU - Runowicz, C. D.

AU - Pollard, J. W.

PY - 1999

Y1 - 1999

N2 - Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25- 50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25-50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.

AB - Objective. Several studies have demonstrated overexpression of the mononuclear phagocytic growth factor colony-stimulating factor-1 (CSF-1) and its receptor (CSF-1R) in breast, ovarian, and endometrial adenocarcinomas, and their expression in each of these cancers is strongly correlated with poor prognosis. In addition to adenocarcinomas, sarcomas that are highly malignant arise at much lower frequency in the uterus. Given the common organ of origin and hormonal environment of the adenocarcinomas, we evaluated the potential role of CSF-1 and CSF-1R in the genesis of these tumors using immunohistochemical methods. Results. Immunohistochemical analysis was performed on 19 archival uterine sarcoma samples. Affinity-purified rabbit anti-CSF-1 antiserum (R52) and human cross-reactive murine anti-c-fms antibody were used. In the 19 cases evaluated for CSF-1 immunoreactivity, 42.1% had staining in less than 25% of the tumor, 36.9% had staining in 25- 50% of the tumor, and only 21% had staining in greater than 50% of the tumor. When present, the majority of the CSF-1 immunostaining was associated with the extracellular matrix. There was variable intensity in CSF-1 expression: 52.6% had negative to mild staining, and 47.4% had moderate to strong staining. Immunostaining for the CSF-1R revealed that 52.6% of tumors had expression in less than 25% of cells, 21.0% had expression in 25-50% of the tumor, and 26.4% had staining in greater than 50% of the tumor. There was variable intensity of CSF-1R staining. Slight staining was found in 31.6% of the cases, moderate staining was found in 47.4% of the tumors, and 21.0% of the cases had strong expression. There was no statistically significant correlation between CSF-1 and CSF-1R expression and stage, estrogen/progesterone receptor status, number of mitoses per 10 high-power fields, or disease outcome. In addition, overall expression and intensity of CSF-1 and CSF-1R did not predict tumor virulence or disease outcome. Conclusion. In contradistinction to endometrial adenocarcinomas, in which CSF-1/CSF-1R is strongly correlated with tumor progression, CSF-1 and CSF-1R overexpression does not appear to play a role in the growth and differentiation of uterine sarcomas.

KW - Colony-stimulating factor-1 (CSF-1)

KW - CSF-1 receptor (c-fms)

KW - Uterine sarcomas

UR - http://www.scopus.com/inward/record.url?scp=0032770538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032770538&partnerID=8YFLogxK

U2 - 10.1006/gyno.1999.5446

DO - 10.1006/gyno.1999.5446

M3 - Article

C2 - 10419732

AN - SCOPUS:0032770538

VL - 74

SP - 202

EP - 207

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -